Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC

BACKGROUND: Targeted therapies offer novel opportunities to explore biomarkers based on their mode of action. Taking this into consideration, we evaluated six angiogenesis-related proteins as potential predictive biomarkers, which expression might predict the benefit of bevacizumab treatment in pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Med Oncol
Hlavní autoři: Bianconi, Daniela, Herac, Merima, Posch, Florian, Schmeidl, Margit, Unseld, Matthias, Kieler, Markus, Brettner, Robert, Müllauer, Leonhard, Riedl, Jakob, Gerger, Armin, Scheithauer, Werner, Prager, Gerald
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446555/
https://ncbi.nlm.nih.gov/pubmed/32922518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920928635
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky